Estamos no ar no ! Saiba mais

Cabaletta Bio

CABA

Valor de mercado US$ 239 mi

1,41 USD

-0,14

9,03%

No fechamento Atualizado 16 de out. 16:00 EDT

Pré-mercado

Após o fechamento do mercado

1,42

+0,01

0,71%

1 dia

-9,03%

5 dias

-27,32%

1 mês

-43,37%

3 meses

-47,19%

6 meses

-59,94%

No acumulado do ano

-36,2%

1 ano

-51,04%

5 anos

-88,93%

10 anos

-85,9%

Sobre: Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

Funcionários: 158

Saúde Biotecnologia

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 0%

Neutro 80%

Negativo 20%

Cabaletta Bio: 40% Sell-Off Creates An Opportunity Despite Cash Concerns

Cabaletta Bio is rated Buy, trading 40% below its $2.41 pipeline value despite a single-asset risk profile. CABA's lead CAR T asset, rese-cel, targets severe autoimmune diseases with pivotal Phase 1/2 data expected mid-2027 and BLA submission planned for late 2027. A recent 10-year manufacturing deal with Cellares lowers future COGS, supporting margin expansion if rese-cel is approved.

Cabaletta Bio: 40% Sell-Off Creates An Opportunity Despite Cash Concerns

Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced the grant of inducement equity awards to four newly hired non-executive employees as a material inducement to commencing their employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Cabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Cabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Cabaletta Bio to Participate in Upcoming Investor Conferences

PHILADELPHIA, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced its participation in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference: Meetings with investors on Tuesday, September 8, 2026, in Boston, MA.

Cabaletta Bio to Participate in Upcoming Investor Conferences

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Registrational RESET-Myositis ® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Cabaletta Bio: The Market Sold The EULAR News, I'm Buying

Cabaletta Bio (CABA) offers a de-risked, breadth-first CAR-T platform for autoimmune diseases, with strong EULAR 2026 data and a compelling $2.90/share entry point. CABA's rese-cel is advancing across five indications, with pivotal myositis and systemic sclerosis trials, clean safety profile, and automated manufacturing via Cellares. Recent $150M raise with participation from Eli Lilly and top biotech funds strengthens CABA's financial runway and strategic optionality, supporting a 2H27 BLA timeline.

Cabaletta Bio: The Market Sold The EULAR News, I'm Buying

Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress

83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through latest follow-up, as long as 1.5 years

Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress

Zacks Investment Research

Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?

Here is how Cabaletta Bio, Inc. (CABA) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.

Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?

Zacks Investment Research

Cabaletta Bio (CABA) Upgraded to Buy: Here's Why

Cabaletta Bio (CABA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Cabaletta Bio (CABA) Upgraded to Buy: Here's Why

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™